• First dosing completed in Phase 2/3 HEALEY ALS Platform Trial for NUZ-001
• Presented preclinical data on NUZ-001 in Huntington's Disease at ASENT 2026
• Strengthened balance sheet with $17.5M in non-dilutive and shareholder funding

Neurizon Therapeutics Limited (ASX: NUZ) provided its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2026. Key highlights include the initiation of participant enrolment and dosing in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial, evaluating NUZ-001 for the treatment of ALS, as well as the presentation of preclinical data on NUZ-001 in Huntington's Disease at the ASENT 2026 annual meeting. The company significantly strengthened its balance sheet, raising $5.88 million through an Entitlement Offer, securing a $6 million cash rebate under the Australian Government's R&D Tax Incentive program, and completing the first tranche drawdown of a $20 million strategic funding facility. Neurizon also secured registered trademark protection for NEURIZON® across key global markets and continued to strengthen its relationship with Elanco Animal Health. The company remains focused on disciplined execution of the HEALEY trial, continued expansion of the evidence base for NUZ-001, and delivery of meaningful near-term milestones.

Neurizon expects to finalize its commercial supply agreement with Elanco in Q4 FY26, receive ethics approval for a liquid formulation PK study in Q4 FY26, and initiate the liquid formulation PK study in Q1 FY27. The company also plans to provide continuous updates on trial enrolment progress in Q4 FY26 and Q1/Q2 FY27, with expected completion of trial enrolment in Q1/Q2 FY27.

Neurizon's near-term focus remains on disciplined execution of the HEALEY ALS Platform Trial, continued expansion of the evidence base for NUZ-001, and delivery of meaningful milestones that can create long-term shareholder value. The company is well-positioned to advance its clinical objectives and invest in broader pipeline opportunities following the significant balance sheet strengthening achieved during the quarter.